<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3007">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04382768</url>
  </required_header>
  <id_info>
    <org_study_id>DNL000004</org_study_id>
    <nct_id>NCT04382768</nct_id>
  </id_info>
  <brief_title>Inhaled Ibuprofen to Treat COVID-19</brief_title>
  <acronym>CórdobaTrail</acronym>
  <official_title>Extended Compassionate Use Program (UCA) With Inhalational Ibuprofen in Patients With Acute Respiratory Pathology, Mediated by COVID-19.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Química Luar SRL</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Council of Scientific and Technical Research, Argentina</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centro de Excelencia en Productos y Procesos Córdoba</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Química Luar SRL</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to evaluate the reduction in severity and progression of lung injury with
      inhaled ibuprofen in patients with severe acute respiratory syndrome due to SARS-CoV-2 virus.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2020</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This is an expanded compassionate use program for patients infected with SARS-CoV-2. All patients or their legally authorized representative must provide written informed consent and the patient will be examined to assess their eligibility. Eligible patients will receive inhalation ibuprofen ate three times a day, plus standard care, until the patient became negative, or their physician considers enough or the patient requested to stop.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the scale of ordinary COVID results at 7, 14 and 28 days in patients with acute respiratory infection, induced by SARS-CoV-2, treated with inhaled Ibuprofen.</measure>
    <time_frame>7, 14 and 28 days</time_frame>
    <description>Time to clinical improvement: defined as time from inhaled Ibuprofen first dose to an improvement of three points from the status on a seven-category ordinary scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change to Negativization of the swab to the following treatment points on day 7, day 14, 21 and 28 after treatment with inhaled Ibuprofen.</measure>
    <time_frame>7, 14 and 28 days</time_frame>
    <description>Negativization of two consecutive pharyngo-nasal swab 24-72 hrs apart</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Chage in length of Hospital stay</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chage in duration of ventilation</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chage in length of Critical Care stay</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average score of National Early Warning (NEWS2) between days 1, 7, 14 and 28.</measure>
    <time_frame>1, 7, 14 and 28</time_frame>
    <description>NEWS2 score 20 points is the maximum and indicates that the patient needs emergent assessment by a clinical team or critical care team and usually transfer to higher level of care.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average change in quick sepsis-related organ failure assessment score (qSOFA) score between day 1, 7, 14 and 28.</measure>
    <time_frame>1, 7, 14 and 28 days</time_frame>
    <description>qSOFA, score for sepsis, a maximum value of 3 indicates high risk qSOFA Scores 2-3 are associated with a 3- to 14-fold increase in in-hospital mortality. Assess for evidence of organ dysfunction with blood testing including serum lactate and calculation of the full SOFA Score.
Patients meeting these qSOFA criteria should have infection considered even if it was previously not.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from first dose to conversion to normal or mild pneumonia</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibiotic requirement</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucocorticoids requirement</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse event</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of serious adverse event</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of deaths from any cause at 28 days</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lymphocyte count</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Coronavirus Infection</condition>
  <condition>Respiratory Disease</condition>
  <condition>SARS (Disease)</condition>
  <arm_group>
    <arm_group_label>Luarprofen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inhaled Hypertonic ibuprofen 50 mg tid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inhaled Hypertonic ibuprofen</intervention_name>
    <description>Standard of care plus lipid ibuprofen 50mg tid</description>
    <arm_group_label>Luarprofen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Provision of written informed consent by the patient OR by the patient's Legal
             Representative.

          2. Confirmed or suspected SARS-CoV-2 infection;

          3. Pneumonia without criteria of severity.

          4. With some of the following conditions:

               -  Diabetes.

               -  Cardiovascular disease.

               -  Chronic kidney disease.

               -  Chronic obstructive pulmonary disease.

               -  Structural diseases of the lung

               -  Immunocompromise.

          5. Patient who presents negative results by rtPCR for SARS CoV-2, in case of being highly
             suspicious, the patient may receive it empirically until the results are obtained.

          6. No unstable bronchial asthma

        Exclusion Criteria:

          1. The doctor considers that participation in the Program is not the best for patients or
             for any condition that prevents the Program from being followed safely.

          2. Patients with a history of unstable bronchial asthma

          3. The patient is allergic to ibuprofen or any of the compounds in the preparation.

          4. Hypersensitivity to the drug, nasal polyps syndrome, angioedema or bronchospasm
             against aspirin or other NSAIDs.

          5. Pregnant or lactating woman, or positive pregnancy test on a pre-dose exam.

          6. Patient who is expected to be transferred to another place other than the place where
             the Program starts, within 7 days of starting it.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dante M Beltramo, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Centro de Excelencia en Productos y Procesos Córdoba</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dante M Beltramo, PhD</last_name>
    <phone>54 9 351 766-8050</phone>
    <email>dantemiguelbeltramo@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nestor H García, MD, PhD</last_name>
    <phone>5493513539948</phone>
    <email>garcia.nestor@conicet.gov.ar</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centro de Excelencia en Productos y Procesos Córdoba</name>
      <address>
        <city>Córdoba</city>
        <zip>5000</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>German Ambasch, MD</last_name>
      <phone>54 9 351 564-2602</phone>
      <email>german.ambasch@yahoo.com.ar</email>
    </contact>
    <contact_backup>
      <last_name>Alexis Doreski, MD</last_name>
      <phone>54 9 11 5800-5058</phone>
      <email>respiramos@yahoo.com.ar</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Argentina</country>
  </location_countries>
  <results_reference>
    <citation>Muñoz AJ, Alasino RV, Garro AG, Heredia V, García NH, Cremonezzi DC, Beltramo DM. High Concentrations of Sodium Chloride Improve Microbicidal Activity of Ibuprofen against Common Cystic Fibrosis Pathogens. Pharmaceuticals (Basel). 2018 May 17;11(2). pii: E47. doi: 10.3390/ph11020047.</citation>
    <PMID>29772761</PMID>
  </results_reference>
  <results_reference>
    <citation>He L, Ding Y, Zhang Q, Che X, He Y, Shen H, Wang H, Li Z, Zhao L, Geng J, Deng Y, Yang L, Li J, Cai J, Qiu L, Wen K, Xu X, Jiang S. Expression of elevated levels of pro-inflammatory cytokines in SARS-CoV-infected ACE2+ cells in SARS patients: relation to the acute lung injury and pathogenesis of SARS. J Pathol. 2006 Nov;210(3):288-97.</citation>
    <PMID>17031779</PMID>
  </results_reference>
  <results_reference>
    <citation>Veljkovic V, Vergara-Alert J, Segalés J, Paessler S. Use of the informational spectrum methodology for rapid biological analysis of the novel coronavirus 2019-nCoV: prediction of potential receptor, natural reservoir, tropism and therapeutic/vaccine target. Version 3. F1000Res. 2020 Jan 27 [revised 2020 Jan 1];9:52. doi: 10.12688/f1000research.22149.3. eCollection 2020.</citation>
    <PMID>32419926</PMID>
  </results_reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 6, 2020</study_first_submitted>
  <study_first_submitted_qc>May 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 11, 2020</study_first_posted>
  <last_update_submitted>June 10, 2020</last_update_submitted>
  <last_update_submitted_qc>June 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Council of Scientific and Technical Research, Argentina</investigator_affiliation>
    <investigator_full_name>Néstor H García</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
    <mesh_term>Respiration Disorders</mesh_term>
    <mesh_term>Respiratory Tract Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibuprofen</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

